Clinical trials do not test therapies on patient populations that reflect the diversity of the people that those therapies serve. In this way, the drug development process is flawed and can only be truly effective for a portion of the population represented in clinical research.
Existing U.S. tax rules, unintentionally, prevent more than 100 million Americans from participating in clinical trials (~27% of the U.S. population). Many of these people represent communities that are grossly underrepresented in clinical research.
Payments made to participants are considered income and must be reported to the IRS, which threatens to disqualify patients from receiving critical benefits from a social welfare program (Medicaid, SNAP, etc). This prevents low-income participants from enrolling in or completing a trial.
Earlier this year, we introduced The Harley Jacobsen Act (H.R. 7418) to Congress, co-sponsored by PA Congressional leaders Mike Kelley and Chrissy Houlahan. The bill seeks to exclude all payments to all participants in all clinical trials from being treated as taxable income: